Efficacy of HER2 ADCs against HER2 inhibitor resistance alterations in the PI3K and MAPK pathways in HER2-positive breast cancer

被引：2
|
作者：
Ferraro, Emanuela
Safonov, Anton
Chen, Yuan
White, Charlie
Marra, Antonio
Ahmed, Mehnaj
Acevedo, Barbara
Dang, Chau T.
Modi, Shanu
Solit, David B.
Norton, Larry
Robson, Mark E.
Reis-Filho, Jorge
Chandarlapaty, Sarat
Razavi, Pedram
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 05期
关键词：
D O I：
10.1158/1538-7445.SABCS22-P4-02-01
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P4-02-01
引用
收藏
页数：3
相关论文
共 50 条
  • [1] HER2/PI3K/AKT pathway in HER2-positive breast cancer: A review
    Pan, Linghui
    Li, Jinling
    Xu, Qi
    Gao, Zili
    Yang, Mao
    Wu, Xiaoping
    Li, Xuesen
    [J]. MEDICINE, 2024, 103 (24)
  • [2] HER2Δ16 expression in HER2-positive breast cancer
    De Yao, Jocelyn Torres
    Sun, Danyu
    Galehouse, Donna
    Shorten, Scott
    Haller, Nairmeen
    Rehmus, Esther Hoogland
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [3] HER2Δ16 expression in HER2-positive breast cancer
    De Yao, Jocelyn Torres
    Sun, Danyu
    Galehouse, Donna
    Shorten, Scott
    Haller, Nairmeen Awad
    Rehmus, Esther Hoogland
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (26)
  • [4] Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
    Horimoto, Yoshiya
    Ishizuka, Yumiko
    Ueki, Yuko
    Higuchi, Toru
    Arakawa, Atsushi
    Saito, Mitsue
    [J]. BMC CANCER, 2022, 22 (01)
  • [5] Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
    Yoshiya Horimoto
    Yumiko Ishizuka
    Yuko Ueki
    Toru Higuchi
    Atsushi Arakawa
    Mitsue Saito
    [J]. BMC Cancer, 22
  • [6] Novel Peptidomimetics for Inhibition of HER2:HER3 Heterodimerization in HER2-Positive Breast Cancer
    Kanthala, Shanthi
    Banappagari, Sashikanth
    Gokhale, Ameya
    Liu, Yong-Yu
    Xin, Gu
    Zhao, Yunfeng
    Jois, Seetharama
    [J]. CHEMICAL BIOLOGY & DRUG DESIGN, 2015, 85 (06) : 702 - 714
  • [7] Understanding the spectrum of HER2 status in breast cancer: From HER2-positive to ultra-low HER2
    Ahuja, Sana
    Khan, Adil Aziz
    Zaheer, Sufian
    [J]. PATHOLOGY RESEARCH AND PRACTICE, 2024, 262
  • [8] Acquired Secondary HER2 Mutations Enhance HER2/MAPK Signaling and Promote Resistance to HER2 Kinase Inhibition in Breast Cancer
    Marin, Arnaldo
    Al Mamun, Abdullah
    Patel, Hima
    Akamatsu, Hiroaki
    Ye, Dan
    Sudhan, Dhivya R.
    Eli, Lisa
    Marcelain, Katherine
    Brown, Benjamin P.
    Meiler, Jens
    Arteaga, Carlos L.
    Hanker, Ariella B.
    [J]. CANCER RESEARCH, 2023, 83 (18) : 3145 - 3158
  • [9] HER2 mutation status in Japanese HER2-positive breast cancer patients
    Endo, Yumi
    Dong, Yu
    Kondo, Naoto
    Yoshimoto, Nobuyasu
    Asano, Tomoko
    Hato, Yukari
    Nishimoto, Mayumi
    Kato, Hiroyuki
    Takahashi, Satoru
    Nakanishi, Ryoichi
    Toyama, Tatsuya
    [J]. BREAST CANCER, 2016, 23 (06) : 902 - 907
  • [10] Inhibition of PI3K pathway improves anti HER2 treatment efficacy in a panel of HER2 positive gastric cancer cell lines
    Gambardella, V.
    Llorca-Cardenosa, M. J.
    Castillo, J.
    Tarazona Llavero, N.
    Huerta, M.
    Rosello Keranen, S.
    Ibarolla-Villava, M.
    Ribas, G.
    Gil, A.
    Cervantes, A.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
12345